Citation: Zhen Li, Peilu Song, Yujie Liu, Xiuyun Sun, Xin Zhai, Yu Rao. Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands[J]. Chinese Chemical Letters, ;2026, 37(3): 111033. doi: 10.1016/j.cclet.2025.111033 shu

Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands

Zhen Li ^{a, 1} ,
Peilu Song ^{b, 1} ,
Yujie Liu ^b ,
Xiuyun Sun ^{c, *,} ,
Xin Zhai ^{a, *,} ,
Yu Rao ^{b, c, *,}

a.
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
b.
State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, Beijing 100084, China
c.
Changping Laboratory, Beijing 102206, China

sunxiuyun622@126.com

zhaixin_syphu@126.com

yrao@tsinghua.edu.cn

Received Date: 24 October 2024
Revised Date: 28 February 2025
Accepted Date: 4 March 2025
Available Online: 4 March 2025

Figures(5)

Interleukin-1 receptor-associated kinase 4 (IRAK4), a key target with both enzymatic and non-enzymatic functions, plays a pivotal role in autoimmune diseases. Previous studies have demonstrated that proteolysis-targeting chimera (PROTAC) molecules targeting IRAK4 can effectively eliminate both its enzymatic and non-enzymatic functions, showing promising therapeutic potential. However, the development of highly potent, synthetically accessible IRAK4-targeting degraders remains a challenge. In this work, through three rounds of PROTAC library construction, screening, and optimization, we successfully identified a representative compound, LZ-07, which proved to be a highly potent degrader with a half-maximal degradation concentration (DC₅₀) value of 1.14 nmol/L. Notably, compared with KT-474, LZ-07 demonstrated comparable degradation activity and superior inhibition of cytokine production, while featuring a simpler synthetic route with optimized IRAK4 and cereblon (CRBN) ligands. LZ-07-induced degradation of IRAK4 led to marked suppression of key cytokines, including interleukin-6 (IL-6), IL-1β, tumor necrosis factor alpha (TNF-α), and IL-10. This study presents LZ-07 as a novel, highly efficient, and synthetically straightforward IRAK4-targeting degrader, offering a promising tool compound for the study of the potential treatment of autoimmune diseases.
- IRAK4-targeting degraders,
- Simplified CRBN ligands,
- Non-enzymatic functions,
- Inflammatory cytokines inhibition,
- Autoimmune diseases
1. [1]
  S. Flannery, A.G. Bowie, Biochem. Pharmacol. 80 (2010) 1981–1991. doi: 10.1016/j.bcp.2010.06.020
2. [2]
  K. Kobayashi, L.D. Hernandez, J.E. Galán, et al., Cell 110 (2002) 191–202. doi: 10.1016/S0092-8674(02)00827-9
3. [3]
  T. Kawai, S. Akira, Nat. Immunol. 11 (2010) 373–384. doi: 10.1038/ni.1863
4. [4]
  P.G. Motshwene, M.C. Moncrieffe, J.G. Grossmann, et al., J. Biol. Chem. 284 (2009) 25404–25411. doi: 10.1074/jbc.M109.022392
5. [5]
  A.P. West, A.A. Koblansky, S. Ghosh, Annu. Rev. Cell Dev. Biol. 22 (2006) 409–437. doi: 10.1146/annurev.cellbio.21.122303.115827
6. [6]
  K. Takeda, S. Akira, Semin. Immunol. 16 (2004) 3–9. doi: 10.1016/j.smim.2003.10.003
7. [7]
  S. De, F. Karim, E. Kiessu, et al., J. Biol. Chem. 293 (2018) 15208–15220. doi: 10.1074/jbc.ra118.003831
8. [8]
  K. Yang, A. Puel, S. Zhang, et al., Immunity 23 (2005) 465–478. doi: 10.1016/j.immuni.2005.09.016
9. [9]
  C.L. Ku, H. von Bernuth, C. Picard, et al., J. Exp. Med. 204 (2007) 2407–2422. doi: 10.1084/jem.20070628
10. [10]
  J.J. O’Shea, S.M. Holland, L.M. Staudt, N. Engl. J. Med. 368 (2013) 161–170. doi: 10.1056/NEJMra1202117
11. [11]
  S. Lavazais, M. Jargosch, S. Dupont, et al., Sci. Transl. Med. 15 (2023) eabj3289. doi: 10.1126/scitranslmed.abj3289
12. [12]
  S. Umar, K. Palasiewicz, K. Van Raemdonck, et al., Cell. Mol. Immunol. 18 (2021) 2199–2210. doi: 10.1038/s41423-020-0433-8
13. [13]
  G. Otto, Nat. Rev. Rheumatol. 17 (2021) 646. doi: 10.1038/s41584-021-00699-8
14. [14]
  S.I. Danto, N. Shojaee, R.S.P. Singh, et al., Arthritis Res. Ther. 21 (2019) 269. doi: 10.1186/s13075-019-2008-6
15. [15]
  Y. Feng, C. Chen, A. Shao, et al., Acta Pharm. Sin. B 14 (2024) 5091–5105. doi: 10.1016/j.apsb.2024.09.008
16. [16]
  M. He, C. Cao, Z. Ni, et al., Signal. Transduct. Target. Ther. 7 (2022) 181. doi: 10.1038/s41392-022-00999-9
17. [17]
  M. Békés, D.R. Langley, C.M. Crews, Nat. Rev. Drug Discov. 21 (2022) 181–200. doi: 10.1038/s41573-021-00371-6
18. [18]
  A. Chen, Y. Zhong, Y. Liu, et al., Chin. Chem. Lett. 34 (2023) 107923. doi: 10.1016/j.cclet.2022.107923
19. [19]
  Z. Kang, S. Li, Y. Li, et al., Chin. Chem. Lett. 36 (2025) 110447. doi: 10.1016/j.cclet.2024.110447
20. [20]
  J. Nunes, G.A. McGonagle, J. Eden, et al., ACS Med. Chem. Lett. 10 (2019) 1081–1085. doi: 10.1021/acsmedchemlett.9b00219
21. [21]
  L. Ackerman, G. Acloque, S. Bacchelli, et al., Nat. Med. 29 (2023) 3127–3136. doi: 10.1038/s41591-023-02635-7
22. [22]
  J. Krönke, N.D. Udeshi, A. Narla, et al., Science 343 (2014) 301–305. doi: 10.1126/science.1244851
23. [23]
  J. Krönke, S.N. Hurst, B.L. Ebert, Oncoimmunology 3 (2014) e941742. doi: 10.4161/21624011.2014.941742
24. [24]
  M. Costacurta, J. He, P.E. Thompson, J. Shortt. J. Pers. Med. 11 (2021) 1185. doi: 10.3390/jpm11111185
25. [25]
  C. Steinebach, A. Bricelj, A. Murgai, et al., J. Med. Chem. 66 (2023) 14513–14543. doi: 10.1021/acs.jmedchem.3c00851
26. [26]
  S.L. Degorce, A. Aagaard, R. Anjum, et al., Bioorg. Med. Chem. 28 (2020) 115815. doi: 10.1016/j.bmc.2020.115815
27. [27]
  G.F. Smith, M.D. Altman, B. Andresen, et al., Bioorg. Med. Chem. Lett. 27 (2017) 2721–2726. doi: 10.1016/j.bmcl.2017.04.050
28. [28]
  S. Ichikawa, H.A. Flaxman, W. Xu, et al., Nature 610 (2022) 775–782. doi: 10.1038/s41586-022-05333-5
29. [29]
  M.W.D. Perry, R. Abdulai, M. Mogemark, et al., J. Med. Chem. 62 (2019) 4783–4814. doi: 10.1021/acs.jmedchem.8b01298
1. [1]
  Zimo Yang , Yan Tong , Yongbo Liu , Qianlong Liu , Zhihao Ni , Yuna He , Yu Rao . Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chinese Chemical Letters, 2024, 35(11): 109577-. doi: 10.1016/j.cclet.2024.109577
2. [2]
  Feifei Wang , Hang Yao , Xinyue Wu , Yijian Tang , Yang Bai , Hui Chong , Huan Pang . Metal–organic framework and its composites modulate macrophage polarization in the treatment of inflammatory diseases. Chinese Chemical Letters, 2024, 35(5): 108821-. doi: 10.1016/j.cclet.2023.108821
3. [3]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
4. [4]
  Weijian Zhang , Xianyu Deng , Liying Wang , Jian Wang , Xiuting Guo , Lianggui Huang , Xinyi Wang , Jun Wu , Linjia Jiang . Poly(ferulic acid) nanocarrier enhances chemotherapy sensitivity of acute myeloid leukemia by selectively targeting inflammatory macrophages. Chinese Chemical Letters, 2024, 35(9): 109422-. doi: 10.1016/j.cclet.2023.109422
5. [5]
  Jing Guo , Zhi-Guo Lu , Rui-Chen Zhao , Bao-Ku Li , Xin Zhang . Nucleic acid therapy for metabolic-related diseases. Chinese Chemical Letters, 2025, 36(3): 109875-. doi: 10.1016/j.cclet.2024.109875
6. [6]
  Dayang Xie , Qiannan Cao , Huapan Fang , Yanhui Li , Huayu Tian . Applications and challenges of biomedical polymer materials in pulmonary diseases. Chinese Chemical Letters, 2026, 37(2): 111032-. doi: 10.1016/j.cclet.2025.111032
7. [7]
  Zhaoyong Kang , Shen Li , Yan Li , Jingfeng Song , Yangrui Peng , Yihua Chen . Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024). Chinese Chemical Letters, 2025, 36(7): 110447-. doi: 10.1016/j.cclet.2024.110447
8. [8]
  Rongrong Zheng , Zuxiao Chen , Qiuyuan Li , Ni Yang , Wenjun Zhang , Chuyu Huang , Linping Zhao , Xin Chen , Hong Cheng , Shiying Li . Endoplasmic reticulum targeting photodynamic oxidizer to boost anti-tumor immunity by intensifying immunogenic cell death in conjunction with IDO1 inhibition. Chinese Chemical Letters, 2025, 36(12): 110865-. doi: 10.1016/j.cclet.2025.110865
9. [9]
  Yifan Feng , Chengjuan Chen , Anqi Shao , Qingyang Zhang , Lan Sun , Hai-Yu Hu , Tiantai Zhang . Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs. Chinese Chemical Letters, 2025, 36(12): 110963-. doi: 10.1016/j.cclet.2025.110963
10. [10]
  Lian Jin , Juan Zhang , Libo Nie , Yan Deng , Ghulam Jilany Khana , Nongyue He . Chitosan nanoparticles act as promising carriers of microRNAs to brain cells in neurodegenerative diseases. Chinese Chemical Letters, 2025, 36(10): 110774-. doi: 10.1016/j.cclet.2024.110774
11. [11]
  Quan Lu , Lulu Zhang , Zihan Chen , Jiajia Lv , Jie Gao , Xinmin Li , Hongyu Li , Wen Shi , Xiaohua Li , Huimin Ma , Zeli Yuan . A lipid droplet-targeting fluorescence probe for monitoring of lipid peroxidation in ferroptosis and non-alcoholic fatty liver disease. Chinese Chemical Letters, 2025, 36(8): 110620-. doi: 10.1016/j.cclet.2024.110620
12. [12]
  Yuhao Jin , Zheng Zhou , Haixiang Han . Revisit the classical [Fe4S4(SR)4]2– molecular clusters: The steric effects of ligands and their structural transformations. Chinese Journal of Structural Chemistry, 2025, 44(9): 100660-100660. doi: 10.1016/j.cjsc.2025.100660
13. [13]
  Jing LIANG , Qian WANG , Junfeng BAI . Synthesis and structures of cdq-topological quaternary and (4, 4, 8)-c topological quinary Zn-MOFs with both oxalic acid and triazole ligands. Chinese Journal of Inorganic Chemistry, 2024, 40(11): 2186-2192. doi: 10.11862/CJIC.20240177
14. [14]
  Weizhong LING , Jingyi LIN , Jianglin ZHU , Yuyi LIANG , Shanshan DAI , Yu LI . Syntheses, structures, and catalytic performances of complexes with 4,4′-dihydroxy-[1,1′-biphenyl]-3,3′-dicarboxylic acid ligands. Chinese Journal of Inorganic Chemistry, 2026, 42(1): 152-160. doi: 10.11862/CJIC.20250204
15. [15]
  Yuge Zhang , Siqi Xu , Chenpeng Chen , Haiyu Xian , Qitao Wen , Yunfeng Lin , Tao Wang . Tetrahedral framework nucleic acids in the prevention and treatment of skin and mucosal diseases: Advances and prospects. Chinese Chemical Letters, 2026, 37(2): 111728-. doi: 10.1016/j.cclet.2025.111728
16. [16]
  Dechao Yuan , Tianying Luo , Qiao Su , Changxing Qu , Meng Pan , Jia Xu , Mingyi Zhang , Yuanchao Luo , Renjian He , Shiwei Liu , Xiang Fang , Hong Duan , Zhiyong Qian . Nanozyme-based catalytic therapeutics: Applications in infectious diseases, cancer therapy, and bone regeneration. Chinese Chemical Letters, 2026, 37(3): 111842-. doi: 10.1016/j.cclet.2025.111842
17. [17]
  Wenjie He , Lin Jing , Wendong Zhang , Xing'an Dong , Yan Zou , Xin Liu , Xin Lv , Peng Chen , Jiazhen Liao , Xiao Zhang , Rong Xiao , Yuechang Wei . Plasmonic metallic Bi-modified defective Bi₄Ti₃O₁₂ nanosheets with upward migrating electrons for efficient photocatalytic NO removal and NO₂ inhibition. Chinese Chemical Letters, 2026, 37(2): 111357-. doi: 10.1016/j.cclet.2025.111357
18. [18]
  Mingyue Luo , Kehui Zhang , Honghong Rao , Jianying Li , Xin Xue , Panpan Sun , Xiaoquan Lu , Zhonghua Xue . A simplified ratiometric fluorescent sensing strategy for enhanced detection of alkaline phosphatase employing Prussian blue nanozymes and commercially available chromogen. Chinese Chemical Letters, 2025, 36(9): 110703-. doi: 10.1016/j.cclet.2024.110703
19. [19]
  Yi Zhou , Wei Zhang , Rong Fu , Jiaxin Dong , Yuxuan Liu , Zihang Song , Han Han , Kang Cai . Self-assembly of two pairs of homochiral M₂L₄ coordination capsules with varied confined space using Tröger's base ligands. Chinese Chemical Letters, 2025, 36(2): 109865-. doi: 10.1016/j.cclet.2024.109865
20. [20]
  Kebo Xie , Qian Zhang , Fei Ye , Jungui Dai . A multi-enzymatic cascade reaction for the synthesis of bioactive C-oligosaccharides. Chinese Chemical Letters, 2024, 35(6): 109028-. doi: 10.1016/j.cclet.2023.109028

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(17)
HTML views(2)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142